JAK1 and mature T-cell and NK-cell non-Hodgkin lymphoma: Moskowitz et al. [37] conducted a study on ruxolitinib (a JAK1 and 2 inhibitor), 20 mg, twice-daily efficacy in patients with refractory/relapsed PTCL or MF.